PAH in systemic sclerosis

Adapted from Hao Y, et al. 2016.4
GI, gastrointestinal; ILD, interstitial lung disease.
About 1 in 10 patients with SSc will develop PAH during their lifetime.3
PAH is a leading cause of death in SSc, and mortality in these patients remains unacceptably high.4 Patients with SSc-PAH have poorer outcomes and almost 3 times higher mortality compared to patients with PAH from other causes.1
"PAH remains one of the major causes of Scleroderma related death. It occurs in 10% of Scleroderma patients. Regular screening for PAH even in those without specific symptoms of PAH results in earlier detection and treatment of PAH. This leads to better outcomes both in terms of quality of life and survival for our patients."
“Patients with systemic sclerosis can deteriorate very quickly between annual visits, even if their initial presentation is relatively mild.”
SSc screening programs can reduce mortality5
Screening in SSc populations enables earlier diagnosis of PAH, facilitating earlier intervention and improving long-term survival.5 Annual cardiopulmonary screening is recommended in all patients with SSc, in order to identify patients who should have a right heart catheterisation to diagnose potential PAH.2

Adapted from Morrisroe K, et al. 2017.2
Survival in incident SSc-PAH patients detected in routine clinical practice compared with those detected as part of a screening program5
